Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking blood flow
to the tumor and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of sorafenib and
erlotinib in treating patients with metastatic or unresectable solid tumors.